Re-rostered FDA Committee Backs Peptide Compounding in 8-6 Vote

An FDA advisory committee overhauled by HHS Secretary Robert F. Kennedy Jr. voted 8 to 6 to allow compounding pharmacies to produce four peptides despite FDA scientists' safety concerns and lack of reproducible chemical formulas. The vote could lead to looser restrictions on unregulated peptide…

An FDA advisory committee that was reorganized by HHS Secretary Robert F. Kennedy Jr. has narrowly voted to support looser restrictions on compounded peptide therapies, despite strong objections from the agency's own scientific staff. The vote took place on the first day of the meeting, which continued on July 24, 2026.

FDA scientists repeatedly told the committee during that first day that there was a lack of evidence about the safety and efficacy of these peptides. They also stated that there is no accepted, reproducible chemical formula for the compounds being considered, raising fundamental questions about their consistency and quality.

Despite these concerns, the FDA's Pharmacy Compounding Advisory Committee PCAC voted 8 to 6, with one abstention, to allow compounding pharmacies to produce four of the seven peptides under scrutiny. These four peptides are variously marketed as therapies for ulcerative colitis, wound healing, inflammatory conditions, obesity, and osteoporosis. The remaining three peptides, which are claimed to treat opioid withdrawal, insomnia or narcolepsy, cerebral ischaemia, migraine, and trigeminal neuralgia, were scheduled for a vote later in the meeting.

Scientific and Safety Objections

Committee members who voted against the proposal argued that the existing bans should remain in place. They pointed to the absence of clinical data to back up any claims, the lack of standardized compositions with different active ingredients present between samples, and the risk of serious adverse effects if the products are not manufactured in sterile conditions.

FDA staff scientists had earlier warned that there was insufficient evidence to support the safety or efficacy of these peptides. The compounds are sold in the unregulated grey market, often labeled "for research use only," and have seen an explosion in use in the United States and other countries. Their popularity has been driven largely by social media influencers and has come to prominence following the widespread use of compounded GLP-1 agonists for weight loss.

Political Context and Industry Ties

Kennedy overhauled the roster of the PCAC ahead of the advisory committee meeting, adding new members with ties to the peptide industry. Some of these new members own clinics that offer peptide therapies to patients. Kennedy has called himself a "big fan" of compounded peptides and has pledged to ease restrictions that were introduced under the Biden administration. In 2023, the Biden administration banned pharmacies from producing 19 peptide formulations due to safety concerns.

Panelists who voted in favor of relaxing the Biden-era ban argued that many of the peptides currently on sale are shipped from China. They claimed it would be safer for users to have them made legally in U.S. pharmacies, where manufacturing can be regulated and monitored.

While the FDA could choose to ignore the advisory committee's recommendation and keep the bans in place, there is already speculation that Kennedy might overrule that decision at the HHS level.

Patient Safety Warnings

A non-profit patient safety organization, the Institute for Safe Medication Practices ISMP , expressed deep concern about the commercial market for compounded peptides. The ISMP said that the market has grown far more quickly than the science supporting it.

Rita Jew, President of the ISMP, made a statement before the advisory committee meeting. "Patients are injecting substances that have never been adequately tested in humans, based on marketing claims the available evidence simply does not support," Jew said. "They deserve to know the risks."

The vote represents a notable shift in the regulatory approach to peptide compounding, though the final decision rests with the FDA and potentially with HHS leadership. The outcome for the remaining three peptides is expected to be determined as the meeting continues.

Peptides referenced: GLP-1.